Jinping Zheng1, Wenhua Jian1, Lin Su2, Wenqiong Xue3
1State Key Lab of Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China; 2Boehringer Ingelheim (China) Investment Co Ltd., Shanghai, People’s Republic of China; 3Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Background
- Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease. The distribution of eosinophil levels may differ between populations and is influenced by allergic or infections responses1; atopy is found to be more prevalent among Caucasian than Asian populations2.
- A patient’s blood eosinophil count (BEC) is an important biomarker to predict the response to inhaled corticosteroids (ICS) for the pharmacological management of patients with COPD3.
- The existing literature on BEC for Chinese patients with stable COPD remains limited.
- In this pooled analysis, we aim to present the profile of blood eosinophil levels in Chinese patients with stable COPD and compare the distribution with that of non-Chinese patients.